The Importance of TIMI 3 flow in primary angioplasty

Original title: Predicitors of suboptimal TIMI flow alter primary angioplasty for acute myocardial infarction: results from the HORIZON-AMI trial. Reference: Adriano Caixeta et al.  Eurointervention 2013;9:220-227

Primary angioplasty showed greater efficacy than thrombolytics but one out of every four patients cannot achieve TIMI 3 flow.

The Horizons-AMI trial randomized 3,602 patients to receive bivalirudin or heparin plus inhibitors IIb IIIa and after angiography a second randomization took place to DES or a conventional stent. The primary objective of this analysis was to evaluate the angiographic predictors of both clinical and suboptimal procedural flow (TIMI <3) after stent implantation. The secondary objective was the impact after three years of suboptimal flow, (TIMI 0-2 versus TIMI 3). Angioplasty was performed in 3,345 patients, (92.9%), of which 2,758, (87.1%), had final TIMI 3 flow.

Those who had TIMI

After 30 days and three years, end TIMI flow

Conclusion:

In this large study the lack of restoration of TIMI 3 flow was associated with older age, past infarction, TIMI flow 0-1, lesion length and was a strong predictor of mortality.

Commentary:

This study shows that the failure to achieve TIMI 3 is associated with higher mortality at three years, than the PAMI, Cadillac and Apex IMA studies had shown at six months. It may be important to have a good pre-hospital service where trained personnel are available to bypass the emergency department and refer the patient directly to the catheterization laboratory. 

Courtesy of Dr Carlos Fava.
Interventional Cardiologist.
Favaloro Foundation.
Buenos Aires, Argentina.

Dr. Carlos Fava para SOLACI.ORG

More articles by this author

CRT 2026 | CUT-DRESS Trial: Lesion Preparation with Cutting Balloon

In-stent restenosis (ISR) continues to represent a relevant clinical challenge in contemporary coronary angioplasty practice. Despite advances in drug-eluting stents, neointimal hyperplasia and suboptimal...

CRT 2026 | Clopidogrel vs Aspirin as Long-Term Monotherapy After Coronary Angioplasty

The use of aspirin as chronic antiplatelet therapy after percutaneous coronary intervention (PCI) has historically been the standard recommended by international guidelines. However, recent...

Bioresorbable devices vs DES in patients at high risk of restenosis. Seven-year follow-up of the COMPARE-ABSORB trial

Studies with second-generation drug-eluting stents (DES) have shown that the rate of target lesion failure (TLF) increases linearly up to 5–10 years of follow-up,...

Sheathless Femoral Impella: A New Strategy to Reduce Vascular Complications in High-Risk PCI?

Patients with complex coronary artery disease or cardiogenic shock undergoing percutaneous coronary intervention (PCI) may benefit from the hemodynamic support provided by percutaneous ventricular...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

CRT 2026 | TAVI-CLOSE Trial: Dual Suture vs Suture + Plug for Vascular Closure After Transfemoral TAVI

The transfemoral approach is the predominant strategy for transcatheter aortic valve implantation (TAVI). Although vascular complications are currently less frequent, they remain relevant determinants...

CRT 2026 | NAVITOR IDE: Hemodynamic Outcomes and 5-Year Durability of an Intra-Annular Self-Expanding Transcatheter Aortic Valve

As TAVI expands into younger populations and patients with lower surgical risk, prosthesis durability has become a key aspect of long-term management. The NAVITOR...

CRT 2026 | CUT-DRESS Trial: Lesion Preparation with Cutting Balloon

In-stent restenosis (ISR) continues to represent a relevant clinical challenge in contemporary coronary angioplasty practice. Despite advances in drug-eluting stents, neointimal hyperplasia and suboptimal...